Mustafa Kaplangoray, K. Toprak, C. Aydın, Ramazan Aslan
{"title":"改良格拉斯哥预后评分与st段抬高型心肌梗死经皮冠状动脉介入治疗患者无血流现象关系的研究","authors":"Mustafa Kaplangoray, K. Toprak, C. Aydın, Ramazan Aslan","doi":"10.18621/eurj.1284893","DOIUrl":null,"url":null,"abstract":"Objectives: No-reflow phenomenon (NRP) is a complication associated with poor clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). The modified Glasgow prognostic score (mGPS) is a novel immune-inflammatory index, derived from C-reactive protein (CRP) and serum albumin levels and has been shown to be associated with prognosis in heart disease. In this study we aimed to investigated the relationship between mGPS and NRP in patients undergoing pPCI for STEMI.\nMethods: A total of 379 patients (aged 59 ± 9.9 years; 54.9% male) were enrollled. The patients were divided into 2 groups:no-reflow (n = 72) and reflow (n = 307). No-reflow was defined as thrombolysis in myocardial infarction (TIMI) ≤ 2 flow. The mGPS of all patients was calculated from blood samples at admission. Logistic regression analysis was performed to determine the independent predictive factors for NRP.\nResults: Mean age, pain to balloon duration, troponin T, white blood cell (WBC), Syntax score, neutrophil to lymphocyte ratio (NLR), glucose level, C-reactive protein level (CRP), diabetic and female patient ratio were higher, while left ventricular ejection fraction, ST segment resolution ratio at 60 min, and serum albumin level were lower in the NRP group.Logistic regression analysis showed that WBC count [Hazard ratio (HR): 0.816, 95% confidence interval (CI): 0.728-0.914, p < 0.001], NLR (HR: 0.482, CI: 0.355-0.654, p < 0.001), pain-to-balloon time (HR: 0.976, CI:0.960-0.991, p = 0.002) and mGPS (HR: 3.213, CI: 1.643- 6.283, p = 0.001) were independent predictive factors for NRP. \nConclusions: Modified GPS is an independent predictive factor for NRP in patients undergoing pPCI for STEMI.","PeriodicalId":22571,"journal":{"name":"The European Research Journal","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigation of the relationship between modified Glasgow prognostic score and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction\",\"authors\":\"Mustafa Kaplangoray, K. Toprak, C. Aydın, Ramazan Aslan\",\"doi\":\"10.18621/eurj.1284893\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: No-reflow phenomenon (NRP) is a complication associated with poor clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). The modified Glasgow prognostic score (mGPS) is a novel immune-inflammatory index, derived from C-reactive protein (CRP) and serum albumin levels and has been shown to be associated with prognosis in heart disease. In this study we aimed to investigated the relationship between mGPS and NRP in patients undergoing pPCI for STEMI.\\nMethods: A total of 379 patients (aged 59 ± 9.9 years; 54.9% male) were enrollled. The patients were divided into 2 groups:no-reflow (n = 72) and reflow (n = 307). No-reflow was defined as thrombolysis in myocardial infarction (TIMI) ≤ 2 flow. The mGPS of all patients was calculated from blood samples at admission. Logistic regression analysis was performed to determine the independent predictive factors for NRP.\\nResults: Mean age, pain to balloon duration, troponin T, white blood cell (WBC), Syntax score, neutrophil to lymphocyte ratio (NLR), glucose level, C-reactive protein level (CRP), diabetic and female patient ratio were higher, while left ventricular ejection fraction, ST segment resolution ratio at 60 min, and serum albumin level were lower in the NRP group.Logistic regression analysis showed that WBC count [Hazard ratio (HR): 0.816, 95% confidence interval (CI): 0.728-0.914, p < 0.001], NLR (HR: 0.482, CI: 0.355-0.654, p < 0.001), pain-to-balloon time (HR: 0.976, CI:0.960-0.991, p = 0.002) and mGPS (HR: 3.213, CI: 1.643- 6.283, p = 0.001) were independent predictive factors for NRP. \\nConclusions: Modified GPS is an independent predictive factor for NRP in patients undergoing pPCI for STEMI.\",\"PeriodicalId\":22571,\"journal\":{\"name\":\"The European Research Journal\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European Research Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18621/eurj.1284893\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18621/eurj.1284893","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:无血流再流现象(NRP)是st段抬高型心肌梗死(STEMI)患者接受原发性经皮冠状动脉介入治疗(pPCI)时临床预后较差的并发症。改良格拉斯哥预后评分(mGPS)是一种新的免疫炎症指数,来源于c反应蛋白(CRP)和血清白蛋白水平,已被证明与心脏病的预后相关。在本研究中,我们旨在探讨STEMI pPCI患者的mGPS和NRP之间的关系。方法:共379例患者(年龄59±9.9岁;(54.9%为男性)。患者分为2组:非回流组(72例)和回流组(307例)。无回流定义为心肌梗死溶栓(TIMI)≤2血流。所有患者的mGPS均由入院时的血液样本计算。采用Logistic回归分析确定NRP的独立预测因素。结果:NRP组患者的平均年龄、疼痛至球囊持续时间、肌钙蛋白T、白细胞(WBC)、Syntax评分、中性粒细胞/淋巴细胞比(NLR)、血糖水平、c反应蛋白水平(CRP)、糖尿病患者及女性患者比例较高,左室射血分数、60 min ST段分辨率、血清白蛋白水平较低。Logistic回归分析显示,WBC计数[危险比(HR): 0.816, 95%可信区间(CI): 0.728 ~ 0.914, p < 0.001]、NLR (HR: 0.482, CI: 0.355 ~ 0.654, p < 0.001)、疼痛至球囊时间(HR: 0.976, CI:0.960 ~ 0.991, p = 0.002)和mGPS (HR: 3.213, CI: 1.643 ~ 6.283, p = 0.001)是NRP的独立预测因素。结论:改良GPS是STEMI行pPCI患者NRP的独立预测因素。
Investigation of the relationship between modified Glasgow prognostic score and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction
Objectives: No-reflow phenomenon (NRP) is a complication associated with poor clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). The modified Glasgow prognostic score (mGPS) is a novel immune-inflammatory index, derived from C-reactive protein (CRP) and serum albumin levels and has been shown to be associated with prognosis in heart disease. In this study we aimed to investigated the relationship between mGPS and NRP in patients undergoing pPCI for STEMI.
Methods: A total of 379 patients (aged 59 ± 9.9 years; 54.9% male) were enrollled. The patients were divided into 2 groups:no-reflow (n = 72) and reflow (n = 307). No-reflow was defined as thrombolysis in myocardial infarction (TIMI) ≤ 2 flow. The mGPS of all patients was calculated from blood samples at admission. Logistic regression analysis was performed to determine the independent predictive factors for NRP.
Results: Mean age, pain to balloon duration, troponin T, white blood cell (WBC), Syntax score, neutrophil to lymphocyte ratio (NLR), glucose level, C-reactive protein level (CRP), diabetic and female patient ratio were higher, while left ventricular ejection fraction, ST segment resolution ratio at 60 min, and serum albumin level were lower in the NRP group.Logistic regression analysis showed that WBC count [Hazard ratio (HR): 0.816, 95% confidence interval (CI): 0.728-0.914, p < 0.001], NLR (HR: 0.482, CI: 0.355-0.654, p < 0.001), pain-to-balloon time (HR: 0.976, CI:0.960-0.991, p = 0.002) and mGPS (HR: 3.213, CI: 1.643- 6.283, p = 0.001) were independent predictive factors for NRP.
Conclusions: Modified GPS is an independent predictive factor for NRP in patients undergoing pPCI for STEMI.